Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOYGZF)

• Drug Name: Retosiban Drug Info
• Synonyms: 820957-38-8; UNII-GIE06H28OX; GSK221149A; GSK-221149A; GIE06H28OX; CHEMBL429736; Retosiban [USAN:INN]; Retosiban (USAN); GSK 221149A; SCHEMBL230301; GTPL8403; DTXSID00231559; PLVGDGRBPMVYPB-FDUHJNRSSA-N; ZINC6718496; BDBM50372608; GSK-221,149-A; SB16762; DB11818; HY-14778; CS-0003555; J3.542.064I; D08986; 2,5-Piperazinedione, 3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-4-oxazolyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-, (3R,6R)-

Indication

Disease Entry	ICD 11	Status	REF
Preterm labour	JB00	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 11340891
  CAS Number: CAS 820957-38-8
  TTD Drug ID: DMOYGZF

Molecule-Related Drug Atlas

Drug(s) Targeting Oxytocin receptor (OTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[3]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[4]
Carbetocin	DMUSLW3	Postpartum haemorrhage	JA43	Approved	[5]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[6]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[7]
Barusiban	DMWI0X3	Androgen deficiency	5A81.1	Phase 2	[8]
FE-202767	DMDGZ1C	Erectile dysfunction	HA01.1	Phase 2	[4]
GSK-557296	DM3ZL2O	Premature ejaculation	HA03.0Z	Phase 2	[9]
Pyrrolidine derivative 13	DM3VA8P	N. A.	N. A.	Patented	[10]
PMID28906174-Compound-figure1g	DMECU90	N. A.	N. A.	Patented	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxytocin receptor (OTR)	TTSCIUP	OXYR_HUMAN	Modulator	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8403).
• [2] The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6.
• [3] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369).
• [5] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
• [6] Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.
• [7] Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
• [8] The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10.
• [9] Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85.
• [10] A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290.